Some patients with heart failure may experience transient changes in kidney function upon transition to sacubitril/valsartan. Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan continuation is unknown.

Editors
Editor-in-Chief
Valentin Fuster, MD, PhD, MACC

CME Editor
Ragavendra R. Baliga, MD

Authors
Safia Chatur, MD
Brian L. Claggett, PhD
Finnian R. McCausland, MD
Jean Rouleau, MD
Michael R. Zile, MD
Milton Packer, MD
Marc A. Pfeffer, MD, PhD
Martin Lefkowitz, MD
John JV McMurray, MD
Scott D. Solomon, MD
Muthiah Vaduganathan, MD, MPH 

Important Dates
Date of Release: April 10, 2023
Term of Approval/Date of CME/MOC Expiration: April 9, 2024